Effect of Lipopolysaccharide on Skeletal Muscle Functions (LPS)

This study is currently recruiting participants.
Verified December 2012 by University of Nottingham
Sponsor:
Information provided by (Responsible Party):
University of Nottingham
ClinicalTrials.gov Identifier:
NCT01423968
First received: August 11, 2011
Last updated: December 3, 2012
Last verified: December 2012

August 11, 2011
December 3, 2012
July 2011
December 2012   (final data collection date for primary outcome measure)
Skeletal Muscle Protein Turnover (muscle tracer incorporation) [ Time Frame: 4 hr following LPS infusion ] [ Designated as safety issue: No ]
Skeletal Muscle Protein Turnover (muscle tracer incorporation) [ Time Frame: 2 and 4 hr following LPS infusion ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01423968 on ClinicalTrials.gov Archive Site
  • Whole body glucose disposal [ Time Frame: 4 h Glucose insulin clamp ] [ Designated as safety issue: No ]
  • Expression of genes that regulate muscle protein balance and insulin signalling [ Time Frame: 4 h following LPS infusion ] [ Designated as safety issue: No ]
  • Whole body glucose disposal [ Time Frame: 4 h Glucose insulin clamp ] [ Designated as safety issue: No ]
  • Expression of genes that regulate muscle protein balance and insulin signalling [ Time Frame: 2 and 4 h following LPS infusion ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Effect of Lipopolysaccharide on Skeletal Muscle Functions
Impact & Time-Course of Effect of Intravenous Lipopolysaccharide Infusion on Skeletal Muscle Protein Turnover and Insulin Sensitivity in Healthy Human Volunteers

The investigators aim to examine how the skeletal muscles of the human volunteers respond to experimental septic conditions to aid understanding of muscle wasting and its biology..

Six healthy men aged 18-30 will be randomly assigned to two metabolic study visits. On the first visit, while resting on a bed, they will have four cannulae inserted including one in the upper thigh, for blood sampling and the infusion of insulin, glucose and normal and tracer amino acids (which allow us to measure muscle protein metabolism). Subjects will receive either injection of purified bacterial product called lipopolysaccharide (LPS) to induce flu-like symptoms or normal saline according to randomization followed by a metabolic test to stimulate muscle synthesis and glucose transport. Three small samples of muscle will be obtained under local anaesthetic from the thigh to measure molecular events in muscle. By performing these measurements, the investigators will determine the consequences of LPS on muscle production and carbohydrate metabolism.

During sepsis, the ability of the body to prevent muscle wasting is impaired resulting in loss of skeletal muscle. In addition, skeletal muscle handling of carbohydrate becomes less efficient. These changes could result in delayed recovery, prolonged rehabilitation and in severe cases mortality of patients. It is still unclear how these changes occur in the human skeletal muscles but animal experiments suggest that protein molecules that are released during sepsis are responsible for these changes. Due to the biological differences between animals and humans in metabolic rate and stability, disease susceptibility and response to infection, simple translation of knowledge from animals to patients could be highly misleading. Therefore, we aim to examine how the skeletal muscles of the human volunteers respond to experimental septic conditions.

Following medical screening, six healthy men aged 18-30 will have two metabolic study visits in a random manner. On the first visit, while resting on a bed, they will have four cannulae inserted including one in the upper thigh, for blood sampling and the infusion of insulin, glucose and normal and tracer amino acids (which allow us to measure muscle protein metabolism). Subjects will receive either injection of purified bacterial product called lipopolysaccharide (LPS) to induce flu-like symptoms or normal saline according to randomization followed by a metabolic test to stimulate muscle synthesis and glucose transport. Three small samples of muscle will be obtained under local anaesthetic from the thigh to measure molecular events in muscle. By performing these measurements, we will determine the consequences of LPS on muscle production and carbohydrate metabolism.

Interventional
Not Provided
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Basic Science
Sepsis
Biological: Lipopolysaccharide infusion
Lipopolysaccharide 4 nanogram/kg body weight
Other Name: Endotoxin
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
8
December 2012
December 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

Male 18-30yrs

Exclusion Criteria:

Clotting disorders Metabolic disease e.g. diabetes, thyroid dysfunction Inflammatory conditions e.g. Crohn's Disease Tobacco smoker Cardiac or Renal pathology Respiratory problems including Asthma Active infectious conditions

Male
18 Years to 30 Years
Yes
Contact: Kanagaraj Marimuthu, MS, MRCS 01158230199 kanagaraj.marimuthu@nottingham.ac.uk
Contact: Paul Greenhaff, PhD 01158230133 paul.greenhaff@nottingham.ac.uk
United Kingdom
 
NCT01423968
B/12/2010
No
University of Nottingham
University of Nottingham
Not Provided
Principal Investigator: Paul L Greenhaff, PhD Professor of Muscle Metabolism, University of Nottingham
University of Nottingham
December 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP